A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

Summary

AVX502, an alphavirus replicon vaccine expressing an influenza HA protein, is a candidate vaccine against influenza. The objectives of this Phase 1 study are to test the safety of the vaccine and the immune response to the vaccine in healthy volunteers 18-40 years of age. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in each arm on one or two occasions over 2 months. The study will last 4 months and will have a total of 8 visits.

Timeline

Start

2007-04

Primary completion

2007-09

Completion

2007-09

Drugs

Indications